



# Administrators Update 2024 Spring ADRC Meeting

**Arijit K Bhaumik, CCRP**

---

**Center Administrator**

Michigan Alzheimer's Disease Research Center  
University of Michigan, Michigan Medicine  
Chair, Administrators Steering Committee



# Administrators Steering Committee Members (2023-2024)



## Director of Administration

Sarah Van Heiden, PhD, MPH

---

**Indiana ADRC**  
Indiana University



## Director, Finance and Business Operations

Jennifer Freund, MHSA, FACHE

---

**KU ADRC**  
University of Kansas



## Administrator

Eric L. Shipp, PhD, MBA

---

**South Texas ADRC**  
UT Health San Antonio



## Center Administrator

Arijit K. Bhaumik, CCRP

---

**Michigan ADRC**  
University of Michigan,  
Michigan Medicine



## Clinical Research Supervisor

Karen Smith

---

**UCSF ADRC**  
University of California,  
San Francisco



# National Institute on Aging




**Cerise Elliott, PhD**  
Program Director,  
Clinical  
Interventions and  
Diagnostics Branch



**Nina Silverberg, PhD**  
Director,  
Alzheimer's Disease  
Centers Program



**Grayson Donley**  
Health Specialist,  
Clinical Interventions  
and Diagnostics  
Branch



**Hannah Rosentreter**  
Manager of Special  
Projects  
National Alzheimer's  
Coordinating Center

# Updates and Revisions

**NACC** THE NIA ALZHEIMER'S DISEASE RESEARCH CENTERS PROGRAM  
**National Alzheimer's Coordinating Center** PORTAL

NACC collaborations | Requesting data | Data Analysis | Publishing | NACC productivity | Data collection | ADRC resources | Search

### ADRC BEST PRACTICES

In 2020-2021, the National Institute on Aging convened a working group (**Contributors**) to update the guidance on best practices for the ADRCs in the acquisition, preparation, and storage of biospecimens. These updated documents are included below by topic, along with best practice recommendations for other areas. The recommendations for annual ADRC External Advisory Committee meetings, which also may be of assistance in preparing ADRC Progress Reports, were developed in 2017.

These best practices are intended to be a resource for new Centers and for Centers who may be embarking on a new line of research. Of importance, they should not be construed as requirements for Center activities.

|                           |                                     |
|---------------------------|-------------------------------------|
| Brain*                    | Consent / Confidentiality*          |
| Cost Recovery*            | Digital Neuropathology*             |
| DNA / RNA / Prote*        | EAC Guidelines*                     |
| Informatics*              | Intellectual Property*              |
| Material Transfer*        | Guidance for Management and Sharing |
| Blood/Urine               | GUIDs                               |
| Rigor and Reproducibility | IPSCs                               |

**EAC BEST PRACTICES** (previously Morris Metric)  
Released – August 2023  
<https://naccddata.org/adrc-resources/best-practices>

## RPPR Guidelines Updated – November 2023

### Revised Progress Report Tables

- Tables A1 - A6
- ORE Core Table E3
- REC Tables G1 & G2

<https://naccddata.org/adrc-resources/progress-reports>

**NACC** THE NIA ALZHEIMER'S DISEASE RESEARCH CENTERS PROGRAM  
**National Alzheimer's Coordinating Center** PORTAL

NACC collaborations | Requesting data | Data Analysis | Publishing | NACC productivity | Data collection | ADRC resources | Search

### PROGRESS REPORTS TO NIA

ADRCs must annually submit progress reports to the NIA and the Administrators Steering Committee annually updates all the needed files and instructions for the ADRC community. If you have questions or comments, please contact Arijit Bhaumik ([arijit@med.umich.edu](mailto:arijit@med.umich.edu)) and Grayson Donley ([grayson.donley@nih.gov](mailto:grayson.donley@nih.gov)) and cc: Nina Silverberg ([silverbergn@mail.nih.gov](mailto:silverbergn@mail.nih.gov)) and Cerise Elliott ([elliottce@mail.nih.gov](mailto:elliottce@mail.nih.gov)).

RPPR Guidelines  
 Research Performance Progress Report (RPPR)

| Admin tables                              | Outreach, Recruitment, and Engagement Core tables                      | Supporting documents  |
|---|--|---|
| A1: Federal funded grants                 | E1: Underrepresented Group Events and Activities                       | Tables G1 & G2: Summary tables for REC Scholars and Trainees / REC Events |
| A2: Non-Federal (e.g. foundation) funding | E2: Summary Table of Underrepresented Group (URG) – Related Activities | Reasons for Diversity Reporting in Progress Reports                       |
| A3: Funding for therapeutic trials        |  |   |
| A4: Training awards                       |  |   |



# Revised Progress Report Tables

Standardized Categories

Separated fields

Core A: Administrative: Your Admin Core Leader (Last name) Your Center PI (Last name)  
Y P20/P30 AG0XXXX-Y

**Table 1. Federal Funded Grants Supported by Resources of the \_\_\_\_\_ - ADRC, Year XX**  
 This table only includes federally funded grants that use any resources of your ADRC. Resources include data, samples, expertise, etc. In the far-right columns, indicate your center's role by answering Yes/No (Y/N). See examples provided in the first 3 rows.  
**NOTE:** If the federal grant is a therapeutic trial, it should only be listed in table A3.

| Principal Investigator<br>Last Name,<br>First Name | Grant Source /<br>Number | Grant Title   | Project Period<br>(mm/dd/yy-mm/dd/yy) | Role of ADRC |                    |     |                |        |                     |                  |
|--|--------------------------|---|---------------------------------------|--------------|--------------------|-----|----------------|--------|---------------------|------------------|
|  |                          |   |                                       | Data<br>Y/N  | Neuroimages<br>Y/N |     | Samples<br>Y/N |        | Participants<br>Y/N | Expertise<br>Y/N |
|  |                          |   |                                       |              | MRI                | PET | Biofluid       | Tissue |                     |                  |
| Adams, Dale  | NIH<br>R01AG1256         | Neuroanatomy in<br>Alzheimer's<br>disease           | 09/01/22-08/30/27                     | Y            | N                  | N   | N              | N      | N                   | N                |
| Katt, Mary A.                                      | NIH<br>R01AG9885         | Genetics in<br>Alzheimer's<br>Disease               | 05/01/22-04/30/27                     | Y            | N                  | N   | Y              | Y      | N                   | Y                |
| Doe, John  | NIH<br>R24AG5643         | Social<br>Determinants of<br>Alzheimer's<br>Disease | 03/01/23-02/28/25                     | Y            | Y                  | N   | N              | N      | Y                   | Y                |
|  |                          |   |                                       |              |                    |     |                |        |                     |                  |

Easy to collate

Streamline Submission System

# RPPR Tables – Next Steps



## Working Group Established



Administrators Steering Committee, KUMC, NACC, and NIA



Flexibility to input data and download tables



Standardized database RPPR tables from ADRCs



Generate visual dashboards for key metrics and reporting



Streamlined submission



Proposal submitted to NACC to be included in renewal



INDIANA ALZHEIMER'S DISEASE RESEARCH CENTER



# RPPR Tables & Dashboard – ADRCs & NIA

Core A: Administrative: Your Admin Core Leader (Last name)

Your Center PI (Last name)  
Y P20/P30 AG0XXXX-Y

**Table 1. Federal Funded Grants Supported by Resources of the \_\_\_\_\_ - ADRC, Year XX**  
This table only includes federally funded grants that use any resources of your ADRC. Resources include data, samples, expertise, etc. In the far-right columns, indicate your center's role by answering Yes/No (Y/N). See examples provided in the first 3 rows.  
**NOTE:** If the federal grant is a therapeutic trial, it should only be listed in table A3.

| Principal Investigator Last Name, First Name | Grant Source / Number | Grant Title                         | Project Period (mm/dd/yy-mm/dd/yy) | Data Y/N | Role of ADRC    |     |             |        |                  |               |
|--|-----------------------|-------------------------------------|------------------------------------|----------|-----------------|-----|-------------|--------|------------------|---------------|
|  |                       |                                     |                                    |          | Neuroimages Y/N |     | Samples Y/N |        | Participants Y/N | Expertise Y/N |
|  |                       |                                     |                                    |          | MRI             | PET | Biofluid    | Tissue |                  |               |
| Adams, Dale                                  | NIH R01AG1256         | Neuroanatomy in Alzheimer's disease | 09/01/22-08/30/27                  | Y        | N               | N   | N           | N      | N                | N             |
| Katt, Mai                                    | NIH                   | Genetics in                         |                                    |          |                 |     |             |        |                  |               |

Core A: Administrative: Your Admin Core Leader (Last name)

Your Center PI (Last name)  
Y P20/P30 AG0XXXX-Y

**Table 2. Non-Federal (e.g. Foundation) Funded Grants Supported by Resources of the \_\_\_\_\_ - ADRC, Year XX**  
This table only includes non-federally funded grants that use any resources of your ADRC. Resources include data, neuroimaging, biofluid/tissue samples, expertise. In the far-right columns, indicate your center's role by answering Yes/No (Y/N).  
**NOTE:** If the federal grant is a therapeutic trial, it should only be listed in table A3.

| Principal Investigator Last Name, First Name | Grant Source            | Grant Title             | Project Period (mm/dd/yy-mm/dd/yy) | Data Y/N | Role of ADRC    |     |             |        |                  |               |
|--|-------------------------|-------------------------|------------------------------------|----------|-----------------|-----|-------------|--------|------------------|---------------|
|  |                         |                         |                                    |          | Neuroimages Y/N |     | Samples Y/N |        | Participants Y/N | Expertise Y/N |
|  |                         |                         |                                    |          | MRI             | PET | Biofluid    | Tissue |                  |               |
| Brown, Nadine                                | Scarf Family Foundation | PET Imaging in Dementia | 01/01/23-12/31/23                  | Y        | N               | N   | N           | N      | N                | N             |
| Ball, Ronald                                 | Alzheimer's Association | Genetics in Alzheimer's | 05/01/23-04/30/24                  | Y        | N               | N   | Y           | N      | N                | Y             |



Core A: Administrative: Your Admin Core PI (Last name)

Your Center PI (Last name)  
Y P20/P30 AG0XXXX-Y

**Table 3. Therapeutic Trials Supported by Resources of the \_\_\_\_\_ ADRC – Year XX**  
This table only includes therapeutic trials. In the far-right column, enter the number of participants referred from your ADRC.  
– U.S. National Institutes of Health = 1; Other U.S. Federal agencies (for example: Food and Drug Administration, Department of Defense, Centers for Disease Control and Prevention, or U.S. Department of Veterans Affairs) = 2; Industry = 3 (for example: pharmaceutical and device companies); All others = 4 (including individuals, universities, and community-based organizations).

| Principal Investigator Last Name, First Name | Funding Source of Trial | Grant Title  | NCT #       | Project Period mm/dd/yy-mm/dd/yy | Number of participants referred |
|--|-------------------------|--|-------------|----------------------------------|---------------------------------|
| Dunn, Shannon                                | 3                       | An Open-Label Study to Evaluate the Safety and Efficacy of *** in Patients with Probable AD              | NCTXXXXXXXX | 09/01/20-03/31/22                | 7                               |
| Jones, Brandon                               | 2, 4                    | A Randomized, Double Blind Study to Evaluate the Efficacy of *** in Older Adults at Risk for Memory Loss | NCTXXXXXXXX | 10/30/22-9/30/24                 | 20                              |
| Yang, Violet                                 | 4                       | A Phase 2 Randomized Study to Evaluate the Safety and Efficacy of *** to Slow the Progression            | NCTXXXXXXXX | 02/10/21-01/10/24                | 6                               |

**37 Centers submit 11 tables**





# **The Alzheimer's Association Approach to an Evolving Alzheimer's and Dementia Landscape**

**Joanne Pike, DrPh**

President and Chief Executive Officer  
Alzheimer's Association





